STAT+: Lilly’s triple-G drug beats Ozempic in head-to-head study

STAT PlusNewsletterThe Readout Lilly’s triple-G drug beats Ozempic in head-to-head study Two deaths reported in cell therapy autoimmune trial, Epic’s dominance over patient data, and more biotech news Manage alerts for this article Save this story for later Share this article By Elaine ChenOct. 28, 2026 National Biotech Reporter Elaine Chen[email protected]Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud.

You can reach Elaine on Signal at elaineywchen.70. Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Good morning. We’ve got lots of news today to get into.Advertisement Lilly’s triple-G drug beats Ozempic in head-to-head study Eli Lilly said this morning that its investigational drug retatrutide was more effective at lowering blood sugar and cutting weight than Novo Nordisk’s Ozempic in a large diabetes study. STAT+ Exclusive Story Already have an account?

Log in This article is exclusive to STAT+ subscribers Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts. Already have an account? Log in Monthly $39 Totals $468 per year $39/month Get Started Totals $468 per year Starter $30 for 3 months, then $399/year $30 for 3 months Get Started Then $399/year Annual $399 Save 15% $399/year Get Started Save 15% 11+ Users Custom Savings start at 25%!

Request A Quote Request A Quote Savings start at 25%! 2-10 Users $300 Annually per user $300/year Get Started $300 Annually per user View All Plans To read the rest of this story subscribe to STAT+. Subscribe Log In biotechnology, drug development, Drug prices, Eli Lilly, Obesity, research, weight loss Submit a correction requestReprints Elaine Chen National Biotech Reporter Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector.

She co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Newsletter Your morning rundown of the science, politics, and money driving biotech today Recommended Pharma October 28, 2026 STAT Plus: Lilly says ‘triple-G’ drug beats Novo’s Ozempic in diabetes study Biotech October 27, 2026 STAT Plus: After two deaths in autoimmune cell therapy trial, Artiva is shutting down Advertisement Biotech October 27, 2026 STAT Plus: FDA offers new details on quicker approval pathway for personalized gene therapies D.C.

Diagnosis October 27, 2026 STAT Plus: RFK Jr. goes for broke in Iowa The Readout October 27, 2026 STAT Plus: Nonprofit resurrects shelved gene therapy after startup shuts down Subscriber Picks